Clusters of differentiation

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Medical specialties, Cytokines, Chemokine receptors, Clusters of differentiation, C-C chemokine receptor type 7, CCL21, Angiology, Dendritic cell, Neuropilin 2, Forward-looking statement, Lymphatic system

\xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.

Key Points: 
  • \xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.
  • In addition, NRP2 modulates interactions between CCL21 and CCR7 potentially impacting homing of dendritic cells to lymphoid organs.
  • All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain.
  • Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.\n'

ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Antibody-drug conjugates, Loncastuximab tesirine, Drugs, Clinical medicine, Pyrrolobenzodiazepine, Clusters of differentiation, CD19, ADC, Biotechnology, ADC Therapeutics, ZYNLONTA™ (loncastuximab tesirine-lpyl), ADC THERAPEUTICS, ZYNLONTA™ (LONCASTUXIMAB TESIRINE-LPYL)

For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .\nZYNLONTA\xe2\x84\xa2 is a trademark of ADC Therapeutics SA.\nZYNLONTA\xe2\x84\xa2is a CD19-directed antibody drug conjugate (ADC).

Key Points: 
  • For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .\nZYNLONTA\xe2\x84\xa2 is a trademark of ADC Therapeutics SA.\nZYNLONTA\xe2\x84\xa2is a CD19-directed antibody drug conjugate (ADC).
  • Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
  • You may also report side effects to ADC Therapeutics at 1-855-690-0340.\nPlease see full Prescribing Information at www.ZYNLONTA.com for ZYNLONTA.\nThis press release contains statements that constitute forward-looking statements.
  • No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005495/en/\n'

Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Immune system, Clusters of differentiation, Cancer immunology, Oncology

XTX101 is specifically designed to target the anti-CTLA-4 effect geographically within the tumor and to minimize off-tumor peripheral effects.

Key Points: 
  • XTX101 is specifically designed to target the anti-CTLA-4 effect geographically within the tumor and to minimize off-tumor peripheral effects.
  • We believe these data validate our approach, and we observed that XTX101 induces tumor-selective biological activity and robust tumor growth inhibition, with favorable tolerability, in preclinical studies.
  • The company\xe2\x80\x99s proprietary pipeline includes XTX202, a tumor-selective modified form of IL-2, and XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody (mAb), as well as tumor-selective IL-12 and IL-15 research programs.
  • For more information, please visit www.xiliotx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005177/en/\n'

Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)

Retrieved on: 
Monday, May 10, 2021
Clusters of differentiation, Branches of biology, TLR9, CPG, Toll-like receptor, CPG

Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component.

Key Points: 
  • Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component.
  • The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information.
  • This list of channels may be updated from time to time on our investor relations website and may include additional social media channels.
  • All information in this press release is as of the date of the release, and Checkmate undertakes no duty to update this information unless required by law.\n'

Eledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress

Retrieved on: 
Wednesday, May 5, 2021
Clusters of differentiation, CD40, CD154, Immunoglobulin G

AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches.

Key Points: 
  • AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches.
  • The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation.
  • Eledon is headquartered in Irvine, Calif. For more information, please visit the company\xe2\x80\x99s website at www.eledon.com .\nFollow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn .\nThis press release contains forward-looking statements that involve substantial risks and uncertainties.
  • Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors.

Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

Retrieved on: 
Wednesday, May 5, 2021
Clusters of differentiation, NT5E, Clinical medicine, Cancer immunotherapy, Medicine, Immunotherapy, Humanized antibody, Monoclonal antibodies

Before purchasing shares, prospective investors should read the prospectus supplement and the accompanying prospectus, together with the documents incorporated by reference therein.

Key Points: 
  • Before purchasing shares, prospective investors should read the prospectus supplement and the accompanying prospectus, together with the documents incorporated by reference therein.
  • Prospective investors may obtain these documents for free by visiting EDGAR on the SEC\xe2\x80\x99s website at www.sec.gov.
  • Corvus\xe2\x80\x99 lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies.
  • Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.

Eledon Pharmaceuticals to Release First Quarter Financial Results on Thursday, May 13, 2021

Retrieved on: 
Tuesday, May 4, 2021
Clusters of differentiation, Medical specialties, Branches of biology, Glycoproteins, CD154, Biology, Immunology, CD40, Immunoglobulin G, Antibody, Immune system

The company\xe2\x80\x99s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.

Key Points: 
  • The company\xe2\x80\x99s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.
  • AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches.
  • The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation.
  • Eledon is headquartered in Irvine, Calif. For more information, please visit the company\xe2\x80\x99s website at www.eledon.com .\nFollow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn .\n'

Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity

Retrieved on: 
Tuesday, May 4, 2021
Medical specialties, Clinical medicine, Medicine, Clusters of differentiation, Immunology, Immune system, CD154, CD40, Monoclonal antibody, Immunotherapy, Antibody

We are focused on the launch of ARCALYST and are confident in our commercialization strategy,\xe2\x80\x9d said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa.

Key Points: 
  • We are focused on the launch of ARCALYST and are confident in our commercialization strategy,\xe2\x80\x9d said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa.
  • \xe2\x80\x9cAdditionally, we are executing across our broader portfolio of immune-modulating assets.
  • Kiniksa believes vixarelimab to be the only monoclonal antibody in development that targets both pathways simultaneously.
  • Kiniksa believes disrupting the CD40-CD154 interaction is an attractive approach for multiple autoimmune disease pathologies.

DGAP-News: VAXIMM Announces Participation at Scientific and Industry Events in May

Retrieved on: 
Tuesday, May 4, 2021
Clinical medicine, Medical specialties, Immune system, Medicine, Clusters of differentiation, Breakthrough therapy, Orphan drugs, Cancer immunotherapy, Avelumab, PD-L1, Natural killer cell, Programmed cell death protein 1

The Company has a pipeline of complementary development candidates targeting different tumor structures.

Key Points: 
  • The Company has a pipeline of complementary development candidates targeting different tumor structures.
  • Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors.
  • As part of a scientific collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., VAXIMM has an ongoing clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab.
  • Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company\'s development activities.

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021

Retrieved on: 
Monday, May 3, 2021
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Selectins, Clusters of differentiation, Proteins, Cell biology, CXCR4, E-selectin, Uproleselan, GMI-1687, GMI-1359, GlycoMimetics, Inc., UPROLESELAN, GMI-1687, GMI-1359, GLYCOMIMETICS, INC.

b"GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2021 and highlighted recent company events.

Key Points: 
  • b"GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2021 and highlighted recent company events.
  • A webcast replay will be available via the \xe2\x80\x9cInvestors\xe2\x80\x9d tab on the GlycoMimetics website for 30 days following the call.
  • Previously, GlycoMimetics demonstrated in preclinical models that GMI-1687 could be a potentially self-administered drug to be used in treatment of AML.
  • GlycoMimetics has an ongoing Phase 1b clinical trial evaluating its wholly-owned drug candidate GMI-1359, a combined CXCR4 and E-selectin antagonist.